1
|
Samadi M, Jelvehgari M, Salatin S. Development and optimization of guaifenesin sustained release mini-tablets for adult and geriatric patients. Ther Deliv 2024; 15:859-869. [PMID: 39360950 PMCID: PMC11497993 DOI: 10.1080/20415990.2024.2406216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Accepted: 09/16/2024] [Indexed: 10/23/2024] Open
Abstract
Aim: The main aim of this study was to formulate and optimize sustained release mini-tablets of guaifenesin.Materials & methods: Guaifenesin granules were successfully prepared using different blend ratios of carnauba wax to drug by melt granulation method. The properties of granules were further modified by combining them with ethyl cellulose. The obtained granules were then mixed and compressed into mini-tablets using a tablet press machine. The resulting mini-tablets were characterized in terms of weight, thickness, hardness, drug content and in vitro drug release.Results: Mini-tablets with 1:6 carnauba wax to drug ratio showed superior physicochemical characteristics, releasing about 100.03% of guaifenesin over 8 h. Ethyl cellulose offers a great potential to accurately control drug release from mini-tablets.Conclusion: The prepared mini-tablets seem to be a very promising alternative to guaifenesin conventional formulations and can be used in adults and elderly people.
Collapse
Affiliation(s)
- Mahshid Samadi
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mitra Jelvehgari
- Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sara Salatin
- Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
2
|
Lyytikäinen J, Kyllönen S, Ervasti T, Komulainen E, Pekarek T, Slunečková J, Leskinen J, Ketolainen J, Kubelka T, Stasiak P, Korhonen O. Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests. Int J Pharm 2023; 647:123509. [PMID: 37832703 DOI: 10.1016/j.ijpharm.2023.123509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 10/07/2023] [Accepted: 10/10/2023] [Indexed: 10/15/2023]
Abstract
As is the case with batch-based tableting processes, continuous tablet manufacturing can be conducted by direct compression or with a granulation step such as dry or wet granulation included in the production procedure. In this work, continuous manufacturing tests were performed with a commercial tablet formulation, while maintaining its original material composition. Challenges were encountered with the feeding performance of the API during initial tests which required designing different powder pre-blend compositions. After the pre-blend optimization phase, granules were prepared with a roller compactor. Tableting was conducted with the granules and an additional brief continuous direct compression run was completed with some ungranulated mixture. The tablets were assessed with off-line tests, applying the quality requirements demanded for the batch-manufactured product. Chemical maps were obtained by Raman mapping and elemental maps by scanning electron microscopy with energy-dispersive X-ray spectroscopy. Large variations in both tablet weights and breaking forces were observed in all tested samples, resulting in significant quality complications. It was suspected that the API tended to adhere to the process equipment, accounting for the low API content in the powder mixture and tablets. These results suggest that this API or the tablet composition was unsuitable for manufacturing in a continuous line; further testing could be continued with different materials and changes in the process.
Collapse
Affiliation(s)
- Jenna Lyytikäinen
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| | - Saini Kyllönen
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| | - Tuomas Ervasti
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| | - Eelis Komulainen
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| | | | | | - Jari Leskinen
- Department of Technical Physics, University of Eastern Finland, Kuopio, Finland.
| | - Jarkko Ketolainen
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| | | | | | - Ossi Korhonen
- School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland.
| |
Collapse
|
3
|
Crystal and Particle Engineering - An Indispensable Tool for Developing and Manufacturing Quality Pharmaceutical Products. Pharm Res 2022; 39:3041-3045. [PMID: 36471027 DOI: 10.1007/s11095-022-03449-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|